Duca, Matteo, Lim, Darren Wan-Teck , Subbiah, Vivek, Takahashi, Shunji, Sarantopoulos, John, Varga, Andrea, D'Alessio, Tony, Abrams, Tinya, Sheng, Qing, Tan, Eugene, Cintrao Dos Santos Rosa, Maria, Gonzalez Maffe, Juan, Sand Dejmek, Janna, Fabre, Claire and Martin, Miguel (2022) A First-in-Human, Phase 1, Multicenter, Open-label, Dose-Escalation Study of PCA062, an Antibody-Drug Conjugate Targeting P-Cadherin, in Adult Patients with Solid Tumors. Molecular cancer therapeutics, 21 (4). pp. 625-634. ISSN 1535-7163

Abstract

Background: This first-in-human (FIH), phase 1, multicenter, open-label study was conducted to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy, and to establish the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) of PCA062 in patients with solid tumors.
Patients and methods: Adult patients with any solid tumor type and having a documented P-cadherin-positive tumor were enrolled; exceptions to P-cadherin positivity requirement were head and neck squamous cell carcinomas (HNSCC) and esophageal squamous cell carcinoma (ESCC). Dose escalation was guided by an adaptive Bayesian logistic regression model with escalation with overdose control to determine the MTD/RDE.
Results: Forty-seven patients were treated at 10 different dose levels of PCA062, ranging from 0.4 to 5.0 mg/kg Q2W administered as a 1-hour intravenous infusion. All enrolled patients discontinued the treatment; primary reason for discontinuation was progressive disease (78.7%). All 47 patients experienced at least one AE, of which 32 patients had a grade ≥3 AE and 37 patients experienced AEs suspected to be study drug related. The MTD of PCA062 was 3.6 mg/kg Q2W and thrombocytopenia was reported as a DLT that was attributed to the known toxicities of the DM1 payload with no P cadherin-related toxicities. PK was proportional, and no patients developed antidrug antibodies, suggesting adequate exposure at the doses tested. One patient out of 47 achieved a partial response and there was no correlation between tumor P-cadherin expression and clinical efficacy.
Conclusions: Due to limited anti-tumor activity at the maximally tolerated dose level, Novartis has terminated clinical development of PCA062 (NCT02375958).

Item Type:	Article
Keywords:	antibody-drug conjugate, P-cadherin, PCA062, solid tumors, first-in-human, phase 1, maximum tolerated dose, recommended dose for expansion
Date Deposited:	20 Apr 2022 00:45
Last Modified:	20 Apr 2022 00:45
URI:	https://oak.novartis.com/id/eprint/41066